Linking Lou Gehrig's Disease with Spinal Muscular Atrophy
New findings may lead to common treatment for both fatal motor neuron conditions
Researchers of motor neuron diseases have long had a hunch that two fatal diseases, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), might somehow be linked. A new study confirms that this link exists.
"Our study is the first to link the two diseases on a molecular level in human cells," said Robin Reed, Harvard Medical School professor of cell biology and lead investigator of the study.
The results will be published online in the September 27 issue of Cell Reports.
A shared molecular pathway is mutated in
ALS and SMA motor neuron diseases
ALS and SMA proteins known as FUS and SMN
physically and functionally interact
The survival of motor neuron, SMN, protein is present in
bodies of the nucleus known as Gemini of Coiled Bodies,
or gems, and are deficient in
human ALS patient fibroblasts
ALS, or Lou Gehrig's disease, which has an adult onset, affects neurons that control voluntary muscles. As a result, muscles start to weaken, and patients eventually lose the ability to move their arms, legs and other parts of the body.
In contrast, patients who have SMA tend to be infants and young children. Symptoms are similar to ALS, with lack of ability to control muscles being the major symptom.
In both diseases, the most common cause of death is the loss of muscle function in the chest, resulting in respiratory failure.
Previous studies have shown that one of the causes of ALS is mutation of the FUS gene, and that a deficiency in the survival of motor neuron (SMN) protein causes SMA disease. The SMN protein is present in bodies in the nucleus known as Gemini of Coiled Bodies, or gems. Reed's lab connected the FUS protein to the SMN protein and the formation of gems in cellular nuclei.
"Nobody really knows what the function of gems are," said Reed. "The consensus so far is that they might be involved in biogenesis of crucial nuclear RNAs."
The researchers arrived at this pathway by studying human fibroblasts, cells that form the basis of connective tissue. "Unlike other studies of ALS and SMA, in which post-mortem tissue is normally used, we used fibroblasts from patients. These cells are easily accessible because they can be obtained from patients' skin and may provide a better idea of what happens in the human body," said Reed.
Reed and colleagues began the study by showing
that the FUS protein is essential for normal gem levels.
Without it, gem levels in ALS fibroblasts
are much lower than in control fibroblasts.
This feature of ALS fibroblasts led the team
to connect the disease with SMA.
Previous studies had shown that when cells
were deficient in SMN protein,
fibroblasts also lacked gems in the nuclei.
The loss of gems is a final result in both the
SMA and ALS pathways and led Reed and her team
to believe that they might, in fact, be part
of one larger pathway.
"The question now is whether the loss of gems is a cause of the disease or a marker for the disease," said Reed.
Reed is hopeful that even if the loss of gems is a marker, it could be used as a diagnostic tool to determine if someone who is presenting symptoms has ALS. "We will need to find out if the loss of gems is applicable to all cases of ALS or if it is specific to ALS patients with mutations in the FUS gene," added Reed.
Either way, Reed feels "This common pathway may mean common treatment and resources."
This work was supported by NIH grants (GM043375 and DP1OD003930), as well as aid from Toyobo Biotechnology Foundation, the ALS Therapy Alliance and the ALS Association.
Harvard Medical School <http://hms.harvard.edu> has more than 7,500 full-time faculty working in 11 academic departments located at the School's Boston campus or in one of 47 hospital-based clinical departments at 16 Harvard-affiliated teaching hospitals and research institutes. Those affiliates include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cambridge Health Alliance, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Pilgrim Health Care, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, and VA Boston Healthcare System.
Original article: http://hms.harvard.edu/content/shared-pathway-links-lou-gehrigs-disease-spinal-muscular-atrophy